Sarepta Therapeutics (NASDAQ:SRPT) saw its stock plummet in premarket trading Friday following the disclosure of a patient death linked to one of its gene therapy trials. According to Bloomberg, the incident occurred during an early-stage study targeting limb-girdle muscular dystrophy.

Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment. A 51-year-old man with limb-girdle muscular dystrophy (LGMD) type 2D/R3 died after receiving Sarepta’s gene therapy candidate SRP-9004 in a Phase I trial,

A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to the company's gene therapies